A detailed history of Harbour Investments, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Harbour Investments, Inc. holds 60 shares of SUPN stock, worth $2,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60
Previous 60 -0.0%
Holding current value
$2,265
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$29.91 - $38.73 $897 - $1,161
-30 Reduced 33.33%
60 $1,000
Q4 2022

Feb 15, 2023

SELL
$31.09 - $37.88 $994 - $1,212
-32 Reduced 26.23%
90 $3,000
Q3 2021

Nov 15, 2021

SELL
$23.54 - $31.39 $8,074 - $10,766
-343 Reduced 73.76%
122 $3,000
Q2 2021

Aug 16, 2021

BUY
$26.72 - $33.19 $320 - $398
12 Added 2.65%
465 $14,000
Q1 2021

Aug 17, 2021

BUY
$24.15 - $31.45 $10,939 - $14,246
453 New
453 $12,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.02B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.